Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0355-2027

Yeastone Broth, 11ML, 10/BOX, used in antibiotic susceptibility testing of mycological clinical specimens Recall

Yeastone Broth, 11ML, 10/BOX, used in antibiotic susceptibility testing of mycological clinical specimens

FDA recall Class II

Ongoing

FDA lists this Class II recall for Yeastone Broth, 11ML, 10/BOX, used in antibiotic susceptibility testing of mycological clinical specimens. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0355-2027
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Oct 19, 2026
FDA report date
Nov 11, 2026
Quantity in commerce
33 US, 54 OUS
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Yeastone Broth, 11ML, 10/BOX, used in antibiotic susceptibility testing of mycological clinical specimens

The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.

Search FDA identifier text

Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.

This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.

FDA code information

YY3462 lot 440400 UDI-DI 848838018817

View the original FDA recall notice

Why was this product recalled?

Affected lot did not meet specifications. Product may report false susceptibility to antifungal agents, specifically within the Azole family.

What actions did Remel, Inc take?

The firm began notifying affected customers on October 19, 2026. Customers were instructed to notify any personnel who needed to be aware of the issue. Customers should review previously reported susceptibility results generated using the affected lot and assess whether retesting is appropriate. Customers should destroy any remaining inventory of the affected lot. Do not use it for any clinical laboratory testing. Customers should complete and return the acknowledgement form accompanying the letter. Firm will replace product or issue credit. If you have any questions, please contact our Technical Services Department at 800-255-6730 (US) or email microbiology.ts.us@thermofisher.com. You should complete the accompanying Acknowledgment Form upon receipt and return to MBD.vigilance@thermofisher.com

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology